Literature DB >> 6559102

Uptake of methotrexate linked to an anti-EL4-lymphoma antibody by EL4 cells.

P Uadia, A H Blair, T Ghose.   

Abstract

To study the mechanism of tumor inhibition, the uptake of methotrexate (MTX) covalently linked to a rabbit IgG antibody against a tumor-associated antigen on the surface of mouse EL4 lymphoma cells (AELG) has been compared with the uptake of free MTX and of MTX covalently linked to normal rabbit IgG (NRG). When EL4 cells were incubated at 37 degrees C with 10 microM free MTX uptake leveled off after 30 min, at 30 pmol/mg protein. In contrast, uptake of both conjugates under these conditions continued throughout an observation period of 6 h. At 6 h the net uptake of MTX bound to AELG was 40 pmol/mg protein and that of MTX bound to NRG was 24 pmol/mg protein. These results show that both MTX-AELG and MTX-NRG conjugates are taken up by EL4 cells. The rate at which EL4 cells took up bound MTX was much slower than that of free MTX but, at 6 h, the net uptake of MTX-AELG exceeded that of the free drug.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6559102     DOI: 10.1007/bf00199245

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  11 in total

1.  Endocytosis of chlorambucil-bound anti-tumor globulin following "capping" in EL4 lymphoma cells.

Authors:  A Guclu; J Tai; T Ghose
Journal:  Immunol Commun       Date:  1975

2.  Uptake of proteins by malignant cells.

Authors:  T GHOSE; R C NAIRN; J E FOTHERGILL
Journal:  Nature       Date:  1962-12-15       Impact factor: 49.962

3.  Studies on the interaction of tritium-labeled aminopterin with dihydrofolic reductase.

Authors:  R SILBER; F M HUENNEKENS; B W GABRIO
Journal:  Arch Biochem Biophys       Date:  1963-03       Impact factor: 4.013

4.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

5.  Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell.

Authors:  I D Goldman; N S Lichtenstein; V T Oliverio
Journal:  J Biol Chem       Date:  1968-10-10       Impact factor: 5.157

6.  The interaction of carrier-bound methotrexate with L1210 cells.

Authors:  B C Chu; J M Whiteley
Journal:  Mol Pharmacol       Date:  1980-05       Impact factor: 4.436

7.  Transport of methotrexate in L1210 cells: effect of ions on the rate and extent of uptake.

Authors:  G B Henderson; E M Zevely
Journal:  Arch Biochem Biophys       Date:  1980-03       Impact factor: 4.013

8.  Covalent binding of methotrexate to immunoglobulins and the effect of antibody-linked drug on tumor growth in vivo.

Authors:  P N Kulkarni; A H Blair; T I Ghose
Journal:  Cancer Res       Date:  1981-07       Impact factor: 12.701

9.  Resistance of resting 3T6 mouse fibroblasts to methotrexate cytotoxicity.

Authors:  L F Johnson; C L Fuhrman; H T Abelson
Journal:  Cancer Res       Date:  1978-08       Impact factor: 12.701

10.  Ligand-induced movement of lymphocyte membrane macromolecules. 3. Relationship between the formation and fate of anti-Ig-surface Ig complexes and cell metabolism.

Authors:  E R Unanue; M J Karnovsky; H D Engers
Journal:  J Exp Med       Date:  1973-03-01       Impact factor: 14.307

View more
  7 in total

1.  In vivo antitumor effect of methotrexate conjugated to a monoclonal IgM antibody specific for stage-specific embryonic antigen-1, on MH-15 mouse teratocarcinoma.

Authors:  S Persiani; B Ballou; W C Shen; H J Ryser; J M Reiland; T R Hakala
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Mab labelled liposomes as selective vehicles for drugs in H.I.V. infected cells.

Authors:  G Rombi; G Piu; S Piro; V Anedda
Journal:  Cytotechnology       Date:  1993-01       Impact factor: 2.058

3.  Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen.

Authors:  T Ghose; S Ferrone; A H Blair; Y Kralovec; M Temponi; M Singh; M Mammen
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.

Authors:  N Brock
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

5.  Antibody directed targeting of methotrexate-containing small unilamellar vesicles.

Authors:  M Singh; G Faulkner; T I Ghose; M Mezei
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Target-selective cytotoxicity of methotrexate conjugated with monoclonal anti-MM46 antibody.

Authors:  N Endo; Y Takeda; K Kishida; Y Kato; M Saito; N Umemoto; T Hara
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  Hydrolysis of methotrexate-immunoglobulin conjugates by liver homogenates and characterization of catabolites.

Authors:  P O Uadia; A H Blair; T Ghose
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.